Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Vorasidenib (Voranigo)

decorative image of the issue cover

Published April 24, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses vorasidenib (Voranigo), tablets, 10 mg and 40 mg, oral.
  • Indication: The treatment of Grade 2 (per WHO 2016, 2021 grading system) astrocytoma or oligodendroglioma with a susceptible IDH1 mutation or IDH2 mutation in adults and pediatric patients aged 12 years and older following surgical intervention. Treatment with vorasidenib should be initiated following confirmation of an IDH1 or IDH2 mutation through a validated test.